ArticleJournal of cheminformatics2026
CReM-pharm: de novo 3D pharmacophore-based design with synthetic accessibility awareness.
Article in Journal of cheminformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
De novo design methodologies have the potential to significantly enhance the exploration of chemical space in the search for promising ligands featuring novel chemotypes. This exploration can be directed through various computational strategies. 3D pharmacophore models, which represent the interaction patterns critical for protein-ligand recognition, can serve as valuable tools for the design of novel compounds. A common limitation of many generative approaches is the low synthetic feasibility of the generated molecular structures. In the present study, we developed a method capable of controllably generating compounds with a relatively high degree of synthetic accessibility by leveraging the CReM framework, while explicitly conforming to a specified 3D pharmacophore model. Evaluation of this approach across a diverse set of protein targets and pharmacophore models of varying complexity demonstrated its effectiveness and highlighted its advantages over the PGMG method, which employs a deep neural network architecture to generate ligands that may exhibit desired 3D geometries upon embedding. The proposed method has been implemented as an open-source tool, CReM-pharm, available at https://github.com/ci-lab-cz/crem-pharm .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.